Efficacy of anti-interleukin-6 receptor antibody (tocilizumab) in colombian patients with takayasu’s arteritis
dc.audience | Comunidad Universidad Icesi - Investigadores | spa |
dc.citation.issue | Suppl 3 | |
dc.citation.volume | 71 | |
dc.contributor.author | Izquierdo, Jorge H. | spa |
dc.coverage.spatial | Berlin de Lat: 52 31 00 N degrees minutes Lat: 52.5167 decimal degrees Long: 013 24 00 E degrees minutes Long: 13.4000 decimal degrees | spa |
dc.date.accessioned | 2017-11-15T16:54:41Z | |
dc.date.available | 2017-11-15T16:54:41Z | |
dc.date.issued | 2013-06-01 | |
dc.description.abstract | Background Takayasu’s arteritis (TA) is a chronic vasculitis that involves aorta and its main branches, where interleukin-6 (IL-6) seems to play a pathogenic role (1,2). The effect in four patients treated with the anti-IL-6 receptor (IL-6R) antibody Tocilizumab was evaluated. Objectives to describe the effect of Tocilizumab in patients of Takayasu’s arteritis. Methods We reviewed the clinical records of 4 patients with TA diagnosed according to current criteria, treated between 2010 and 2011 in a tertiary center in Cali, Colombia. Four patients with a refractory disease to multiple treatments, was began treatment with Tocilizumab at a dose of 8 mg/kg every month in association with metothrexate and/or steroids. Two patients were treated previously with infliximab (IFX) without control of disease. This cases were reported previously (3). Results The cases summaries are as follows: Case 1. A 30 year-old woman with a diagnosis of TA since 2003 presented panaortitis, with involvement of supra-aortic, | spa |
dc.format.extent | 1 página | spa |
dc.format.medium | Digital | spa |
dc.identifier.doi | http://dx.doi.org/10.1136/annrheumdis-2012-eular.743 | |
dc.identifier.instname | instname:Universidad Icesi | |
dc.identifier.reponame | reponame:Biblioteca Digital | |
dc.identifier.repourl | repourl:https://repository.icesi.edu.co/ | |
dc.identifier.uri | http://hdl.handle.net/10906/82270 | |
dc.language.iso | eng | spa |
dc.publisher | BMJ Publishing Group Ltd | spa |
dc.publisher.department | Departamento de Ciencias Básicas Médicas | spa |
dc.publisher.faculty | Facultad de Ciencias de la Salud | spa |
dc.publisher.place | Berlin | spa |
dc.publisher.program | Medicina | spa |
dc.relation.citationendpage | 681 | |
dc.relation.citationstartpage | 681 | |
dc.relation.ispartof | Annual European Congress of Rheumatology 6 – 9 June -2012 | |
dc.rights | EL AUTOR, expresa que la obra objeto de la presente autorización es original y la elaboró sin quebrantar ni suplantar los derechos de autor de terceros, y de tal forma, la obra es de su exclusiva autoría y tiene la titularidad sobre éste. PARÁGRAFO: en caso de queja o acción por parte de un tercero referente a los derechos de autor sobre el artículo, folleto o libro en cuestión, EL AUTOR, asumirá la responsabilidad total, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos, la Universidad Icesi actúa como un tercero de buena fe. Esta autorización, permite a la Universidad Icesi, de forma indefinida, para que en los términos establecidos en la Ley 23 de 1982, la Ley 44 de 1993, leyes y jurisprudencia vigente al respecto, haga publicación de este con fines educativos Todo persona que consulte ya sea la biblioteca o en medio electrónico podrá copiar apartes del texto citando siempre la fuentes, es decir el título del trabajo y el autor. | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | |
dc.rights.license | Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject.proposal | Arteritis de Takayasu | spa |
dc.subject.proposal | Ciencias socio biomédicas | spa |
dc.subject.proposal | Medical sciences | spa |
dc.subject.proposal | Vasculitis | spa |
dc.subject.proposal | Interleucina-6 | spa |
dc.subject.proposal | Tratamiento farmacológico | spa |
dc.title | Efficacy of anti-interleukin-6 receptor antibody (tocilizumab) in colombian patients with takayasu’s arteritis | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_c94f | |
dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |
dc.type.driver | info:eu-repo/semantics/conferenceObject | spa |
dc.type.local | Documento de conferencia | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |